United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine 10 mg - tranylcypromine sulfate is indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. tranylcypromine sulfate is not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5), and drug interactions (7)] . concomitant use of tranylcypromine sulfate or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)]. medication-free periods between administration of tranylcypromine sulfate and contraindicated agents are recommended [ see dosage and administration (2.2) and drug interactions (7.1) ]. table 1: products contraindicated with the use of tranylcypromine sulfate - other monoamine oxidase inhibitors (maois) - selective se

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

alkaloid-int d.o.o. - paracetamol, phenylephrine (phenylephrine hydrochloride) - powder for oral solution - 1000mg+12,2mg

United States - English - NLM (National Library of Medicine)

akorn - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

alvogen inc. - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine tablets are indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. tranylcypromine tablets are not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5) , and drug interactions (7)]. concomitant use of tranylcypromine tablets or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)]. medication-free periods between administration of tranylcypromine tablets and contraindicated agents are recommended [see dosage and administration (2.2) and drug interactions (7.1)]. table 1: products contraindicated with the use of tranylcypromine tablets - other monoamine oxidase inhibitors (maois) - s

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - physostigmine salicylate (unii: 2046zro9vu) (physostigmine - unii:9u1vm840sp) - to reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. physostigmine salicylate injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). for post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. 2.0 mg intramuscularly or intravenously at slow controlled rate (see above). dosage may be repeated if life threatening signs, such as arrhythmia, convulsions or coma occurs.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine sulfate is indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. tranylcypromine sulfate is not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5), and drug interactions (7)] . concomitant use of tranylcypromine sulfate or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)]. medication-free periods between administration of tranylcypromine sulfate and contraindicated agents are recommended [ see dosage and administration (2.2) and drug interactions (7.1) ]. table 1: products contraindicated with the use of tranylcypromine sulfate - other monoamine oxidase inhibitors (maois) - selective se

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals, inc. - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine tablets are indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. tranylcypromine tablets are not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5), and drug interactions (7)] . concomitant use of tranylcypromine tablets or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)] . medication-free periods between administration of tranylcypromine tablets and contraindicated agents are recommended [see dosage and administration (2.2) and drug interactions (7.1)]. table 1: products contraindicated with the use of tranylcypromine tablets - other mono

United States - English - NLM (National Library of Medicine)

lannett company, inc. - tranylcypromine sulfate (unii: 7zat6es870) (tranylcypromine - unii:3e3v44j4z9) - tranylcypromine tablets are indicated for the treatment of major depressive disorder (mdd) in adult patients who have not responded adequately to other antidepressants. tranylcypromine tablets are not indicated for the initial treatment of mdd due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see contraindications (4), warnings and precautions (5), and drug interactions (7)] . concomitant use of tranylcypromine tablets or use in rapid succession with the products in table 1 is contraindicated. such use may cause severe or life-threatening reactions such as hypertensive crises or serotonin syndrome [see drug interactions (7.1)] . medication-free periods between administration of tranylcypromine tablets and contraindicated agents are recommended [see dosage and administration (2.2) and

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - foslevodopa; foscarbidopa - solution for infusion - dopa and dopa derivatives